BRPI0504117A - epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção - Google Patents

epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção

Info

Publication number
BRPI0504117A
BRPI0504117A BRPI0504117-1A BRPI0504117A BRPI0504117A BR PI0504117 A BRPI0504117 A BR PI0504117A BR PI0504117 A BRPI0504117 A BR PI0504117A BR PI0504117 A BRPI0504117 A BR PI0504117A
Authority
BR
Brazil
Prior art keywords
epitopes
composition
combination
hiv
vaccines
Prior art date
Application number
BRPI0504117-1A
Other languages
English (en)
Inventor
Edecio Cunha Neto
Jorge Elias Kalil Jr
Simone Goncalves Da Fonseca
Original Assignee
Fundacao De Amparo A Pesquisa
Fundacao Zerbini
Univ Sao Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao De Amparo A Pesquisa, Fundacao Zerbini, Univ Sao Paulo filed Critical Fundacao De Amparo A Pesquisa
Priority to BRPI0504117-1A priority Critical patent/BRPI0504117A/pt
Priority to EP11180972A priority patent/EP2397489A1/en
Priority to EP06775031.5A priority patent/EP1937711B1/en
Priority to PCT/BR2006/000175 priority patent/WO2007028219A1/en
Publication of BRPI0504117A publication Critical patent/BRPI0504117A/pt
Priority to US12/073,401 priority patent/US8338582B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"EPìTOPOS, COMBINAçãO DE EPìTOPOS, USOS DE EPìTOPOS OU SUA COMBINAçãO, COMPOSIçãO,USOS DA COMPOSIçãO, VACINAS PROFILáTICAS ANTI-HIV-1, VACINAS TERAPêUTICAS, MéTODO PARA A IDENTIFICAçãO DE EPìTOPOS E MéTODOS PARA O TRATAMENTO OU PREVENçãO" A presente invenção refere-se a novos epítopos reconhecidos por linfócitos T CD4+. Ainda, a presente invenção refere-se ao usos de ditos epítopos e suas combinações, particularmente no tratamento ou prevenção de distúrbios causados pelo vírus HIV-1. A presente invenção refere-se também a uma composição que compreende ditos epítipos e aos usos de dita composição, particularmente no tratamento ou prevenção de distúrbios causados pelo HIV-1. Outro objeto da presente invenção são vacinas, profiláticas anti-HIV-1 ou terapêuticas. Adicionalmente, a presente invenção trata de um método para a identificação de epítopos e métodos de tratamento ou prevenção de uma infecção causada pelo vírus HIV-1.
BRPI0504117-1A 2005-09-05 2005-09-05 epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção BRPI0504117A (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0504117-1A BRPI0504117A (pt) 2005-09-05 2005-09-05 epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
EP11180972A EP2397489A1 (en) 2005-09-05 2006-09-04 Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-HIV-I prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
EP06775031.5A EP1937711B1 (en) 2005-09-05 2006-09-04 Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
PCT/BR2006/000175 WO2007028219A1 (en) 2005-09-05 2006-09-04 Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
US12/073,401 US8338582B2 (en) 2005-09-05 2008-03-05 Anti-HIV immunogens and methods for inducing an immune response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0504117-1A BRPI0504117A (pt) 2005-09-05 2005-09-05 epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção

Publications (1)

Publication Number Publication Date
BRPI0504117A true BRPI0504117A (pt) 2007-05-22

Family

ID=37835320

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0504117-1A BRPI0504117A (pt) 2005-09-05 2005-09-05 epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção

Country Status (4)

Country Link
US (1) US8338582B2 (pt)
EP (2) EP2397489A1 (pt)
BR (1) BRPI0504117A (pt)
WO (1) WO2007028219A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068765A2 (en) * 2006-12-07 2008-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
US20130195904A1 (en) * 2010-01-04 2013-08-01 National University Of Singapore Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CN104163857B (zh) * 2014-08-12 2017-02-15 中国人民解放军军事医学科学院微生物流行病研究所 一种hiv‑1多表位重组蛋白及其编码基因与应用
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
WO2020248032A1 (pt) * 2019-06-10 2020-12-17 Ricardo Diaz Método para a definição de uma vacina personalizada contra o hiv/aids
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591227B1 (fr) * 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
DE69828414T2 (de) * 1997-09-11 2005-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mukosale zytotoxische t-lymphozytenantwort
DE19907485B4 (de) * 1999-02-12 2008-01-17 Strathmann Ag & Co. Virus-Vakzine
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CN1423698A (zh) 1999-11-16 2003-06-11 真那特应用生物科技有限公司 Hiv－1亚型间(c/b’)基因组和其用途
US7655774B2 (en) * 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2003046176A2 (en) * 2001-11-26 2003-06-05 Hybrigenics Protein-protein interactions in human immunodeficiency virus
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
DE10257771A1 (de) * 2002-12-10 2004-07-08 Ruprecht-Karls-Universität Heidelberg Inhibierung der HIV Replikation durch Expression von 'late domain' Peptiden in Zielzellen
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
GB0323840D0 (en) * 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines

Also Published As

Publication number Publication date
EP1937711A4 (en) 2009-07-01
EP2397489A1 (en) 2011-12-21
US8338582B2 (en) 2012-12-25
US20080260766A1 (en) 2008-10-23
EP1937711A1 (en) 2008-07-02
EP1937711B1 (en) 2014-06-11
WO2007028219A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
BR112022020539A2 (pt) Compostos específicos para proteína s de coronavírus e usos dos mesmos
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
BR0313266A (pt) Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
BR112022003046A2 (pt) Conjugados de il-15 e usos dos mesmos
BRPI1003162A8 (pt) Composições para tratamento da sensibilidade dental
ZA202000680B (en) Obinutuzumab treatment of a dlbcl patient subgroup
BR112022010826A2 (pt) Anticorpos amplamente neutralizantes contra o hiv
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
BRPI0411085A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
BR112017014304A2 (pt) ?método para a ativação de nf-kb?

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]